The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation
Authors' conclusion
Our findings indicate an increase in osteoclast precursors, which could explain the overshoot phenomenon observed after discontinuing denosumab.
Study context
- Population
- Postmenopausal women with osteopenia or osteoporosis
- Participants
- 30 women
- Exposure
- Denosumab-treated vs treatment-naïve controls
- Denosumabn = 15
- Controlsn = 15reference
- Outcome
- Osteoclast precursors (CD14+/MCSFR+, CD14+/CD11b+ or CD14+/TNFRII+) in peripheral blood by fluorescent activated cell sorting, as % of total cells
Methodological detailsobservational
- Observational
Main finding
As reported in the abstract
CD14+/CD11b+ osteoclast precursors
P = 0.011
Observational data: associations, not effects.
Further findings
Correlation with treatment duration
- No correlation with the duration of treatment
Bone turnover markers (serum P1NP, CTX, TRACP5b)
- Bone turnover markers significantly lower with Denosumab than controls
Original publication
The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation. J Bone Miner Res. Published 17 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →